Vertex Pharmaceuticals Incorporated
LSE: 0QZU.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Reshma Kewalramani
- Employees
- 6,100
- Headquarters
- Boston, United States
- IPO year
- 2014
- Market cap
- $109.4B
- Website
- https://www.vrtx.com
Loading 0QZU…
Loading profile data…Frequently asked questions about 0QZU
What does Vertex Pharmaceuticals Incorporated (0QZU.L) do?
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
Where does 0QZU.L trade?
Vertex Pharmaceuticals Incorporated (0QZU.L) trades on the London Stock Exchange.
What sector is 0QZU.L in?
Vertex Pharmaceuticals Incorporated (0QZU.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Vertex Pharmaceuticals Incorporated?
Reshma Kewalramani is the chief executive officer of Vertex Pharmaceuticals Incorporated (0QZU.L).
Where is Vertex Pharmaceuticals Incorporated headquartered?
Vertex Pharmaceuticals Incorporated is headquartered in United States.
Does 0QZU.L pay a dividend?
Vertex Pharmaceuticals Incorporated (0QZU.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0QZU.L go public?
Vertex Pharmaceuticals Incorporated (0QZU.L) completed its initial public offering in 2014.